moa of glp-1 agonists Glucagon-like peptide-1 GLP-1 receptor agonists (GLP-1RAs): cardiovascular

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Individual results vary

To evaluate changes in time-in-therapeutic INR range (TTR) among warfarin patients initiated on GLP-1 RA therapy

Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users

The triagonist-induced increase in GSIS was unchanged in the absence of either Gipr or Gcgr

Read more at straitstimes.com